Citigroup’s SomaLogic, Inc. Class A Common Stock SLGC Stock Holding History

Citigroup’s Portfolio SLGC Stock Details SLGC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-22,203	Closed	-$56.2K	–	5953
2023 Q4	$56.2K	Buy	22,203 +21,338	+2,467%	+$49.7K	﹤0.01%	4460
2023 Q3	$2.07K	Sell	865 -48,175	-98%	-$107K	﹤0.01%	4946
2023 Q2	$113K	Buy	49,040 +45,506	+1,288%	+$128K	﹤0.01%	4183
2023 Q1	$9.01K	Sell	3,534 -902	-20%	-$2.58K	﹤0.01%	4775
2022 Q4	$11.1K	Sell	4,436 -1,196	-21%	-$3.34K	﹤0.01%	4804
2022 Q3	$16K	Sell	5,632 -6,977	-55%	-$29.4K	﹤0.01%	4833
2022 Q2	$57K	Sell	12,609 -30,467	-71%	-$181K	﹤0.01%	4482
2022 Q1	$345K	Buy	+43,076	New	+$380K	﹤0.01%	3751

Citigroup's SLGC Position: Q1 2024 in Review

Citigroup sold out of SomaLogic, Inc. Class A Common Stock (SLGC) in Q1 2024, closing a stake of 22,203 shares — an estimated $56.2K sold.

Citigroup first reported a position in SLGC in Q1 2022 and held it in 8 quarters. The position peaked at $345K in Q1 2022. 0 funds tracked by Wall St. Rank hold SLGC as of Q1 2024.

Citigroup reported no remaining SomaLogic, Inc. Class A Common Stock position as of Q1 2024 after selling out during the quarter.
Citigroup sold 22,203 SomaLogic, Inc. Class A Common Stock shares in Q1 2024, an estimated $56.2K.
Citigroup first reported a position in SomaLogic, Inc. Class A Common Stock in Q1 2022 and held it in 8 quarters.
Citigroup's SomaLogic, Inc. Class A Common Stock position peaked at $345K in Q1 2022.
0 funds tracked by Wall St. Rank held SomaLogic, Inc. Class A Common Stock as of Q1 2024.

Based on Citigroup's 13F filing for Q1 2024, filed 10 May 2024.